Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.
In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency.
The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab.
Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 12, 24 | -0.10 Decreased by -392.00% | - |
| Sep 5, 24 | -0.09 Decreased by N/A% | -0.01 Decreased by -762.00% |
| May 15, 24 | -0.06 Decreased by -219.50% | - |
| Nov 17, 23 | 0.00 Decreased by N/A% | - |
| Sep 7, 23 | -0.02 Increased by +85.64% | -0.02 |
| May 31, 23 | 0.00 Decreased by -100.00% | - |
| Mar 28, 23 | -0.02 Increased by +91.61% | - |
| Aug 11, 21 | 0.00 Increased by +100.00% | -0.14 Increased by +100.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by -100.00% | -15.00 M Decreased by -128.68% | - - |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -12.26 M Increased by +9.90% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -8.95 M Increased by +25.88% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 361.10 K Decreased by -89.87% | -6.05 M Increased by +65.76% | Decreased by -1.67 K% Decreased by -237.95% |
| Sep 30, 23 | 533.43 K Decreased by -20.97% | -6.56 M Increased by +73.58% | Decreased by -1.23 K% Increased by +66.57% |
| Jun 30, 23 | 8.79 M Increased by +N/A% | -13.60 M Decreased by N/A% | Decreased by -154.74% - |
| Mar 31, 23 | 0.00 Decreased by N/A% | -12.08 M Decreased by N/A% | Decreased by N/A% - |
| Dec 31, 22 | 3.56 M Increased by +N/A% | -17.66 M Decreased by N/A% | Decreased by -495.48% - |